Efficacy and early discontinuation predictors in NSCLC patients receiving nivolumab

MRTX9768: a synthetic lethal-based inhibitor designed to bind the PRMT5 MTA complex and target MTAP/CDKN2A-deleted tumours

Palliative Care: Industry and Academia – Tensions and Opportunities

Anti-tumour activity and tolerability of RMC-4630 as a single agent in patients with RAS-addicted solid cancers

Mechanisms of acquired resistance to KRAS G12C inhibition in cancer

OncoAlert and ecancer weekly roundup for April 19 - 25, 2021

Language and understanding: The complexity of insight in cancer care

Decolonising palliative care

Understanding patient experience in Europe: The first Global Lung Cancer Coalition Patient Experience Survey

CONVERT trial: Patterns of relapse following thoracic radiotherapy in patients with limited-stage SCLC

First-line osimertinib in EGFR mutant aNSCLC patients: Progression pattern and safety in the real-world

AMG 757: DLL3 targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer